Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Add as a preferred source on Google
NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits against MiMedx Group Inc. (Nasdaq:MDXG), if they purchased the Company’s securities between the expanded period of March 7, 2013 and February 21, 2018, inclusive (the “Class Period”). These actions are pending in the United States District Courts for the Northern District of Georgia and Southern District of New York.
Get Help
MiMedx investors should visit us at https://www.claimsfiler.com/cases/view-mimedx-group-inc-securities-litigation-2 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
MiMedx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 20, 2018, MiMedx revealed it postponed its 2017 earnings report and “engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices.” Then, on February 22, 2018, media reports revealed that MiMedx had “financial ties to more than 20 doctors” that it had not disclosed to the government, which MiMedx claimed was not required.
On this news, the price of MiMedx’s shares plummeted.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
